Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Apr 2017
Changes in systemic immune response after stereotactic ablative radiotherapy. Preliminary results of a prospective study in patients with early lung cancer.
INTRODUCTION Non‑small cell lung cancer (NSCLC) is the most common lung tumor. Conventional conservative treatment in medically inoperable patients with early stage NSCLC has poor outcome. To improve treatment efficacy, stereotactic ablative radiotherapy (SABR) has been developed, which enables the delivery of high‑dose radiation to the tumor. ⋯ We observed slight lymphopenia, which correlated with irradiated lung volume. After SABR, the proportion of CD8(+), CD4(+), as well as the proportion of CD4(+) T cells expressing GATA‑3(+), T‑bet(+), or ROR‑γt(+) increased, while the number of CD4(+)FoxP3(+) cells (specific for regulatory T cells) decreased. CONCLUSIONS Our findings may suggest that SABR enhances the systemic immune response by increasing the proportion of proinflammatory T‑cell subpopulations.